Rhythm Pharmaceuticals Inc. [RYTM] stock is trading at $50.00, up 8.41%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RYTM shares have gain 6.16% over the last week, with a monthly amount glided 1.94%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc. [NASDAQ: RYTM] stock has seen the most recent analyst activity on May 08, 2024, when BofA Securities downgraded its rating to a Neutral and also revised its price target to $42 from $49. Previously, Morgan Stanley upgraded its rating to Overweight on December 19, 2023, and elevated its price target to $55. On August 01, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $27 on the stock. Goldman upgraded its rating to a Buy but $28 remained the price target by the analyst firm on August 08, 2022. BofA Securities upgraded its rating to Neutral for this stock on August 05, 2022, and upped its price target to $20. In a note dated June 17, 2022, Needham reiterated an Buy rating on this stock and revised its target price from $40 to $25.
Rhythm Pharmaceuticals Inc. [RYTM] stock has fluctuated between $20.97 and $53.92 over the past year. Currently, Wall Street analysts expect the stock to reach $38.33 within the next 12 months. Rhythm Pharmaceuticals Inc. [NASDAQ: RYTM] shares were valued at $50.00 at the most recent close of the market. An investor can expect a potential drop of -23.34% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
Rhythm Pharmaceuticals Inc. [NASDAQ:RYTM] reported sales of 101.78M for the trailing twelve months, which represents a growth of 51.28%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -2.61%, Pretax Profit Margin comes in at -2.54%, and Net Profit Margin reading is -2.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.68, Equity is -2.22 and Total Capital is -0.81. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 6.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.59 points at the first support level, and at 45.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 51.26, and for the 2nd resistance point, it is at 52.52.
Ratios To Look Out For
For context, Rhythm Pharmaceuticals Inc.’s Current Ratio is 6.53. Also, the Quick Ratio is 6.31, while the Cash Ratio stands at 2.95. Considering the valuation of this stock, the price to sales ratio is 30.03, the price to book ratio is 77.65.
Transactions by insiders
Recent insider trading involved JENNIFER GOOD, Director, that happened on Aug 26 ’24 when 35000.0 shares were purchased. Director, LYNN TETRAULT393 COMMONWEALTH completed a deal on Aug 26 ’24 to buy 7499.0 shares. Meanwhile, Officer PAMELA CRAMER bought 7299.0 shares on Aug 26 ’24.
